Synonyms: S20098 | Thymanax® | Valdoxan®
agomelatine is an approved drug (EMA (2009))
Compound class:
Synthetic organic
Comment: Agomelatine is a melatonergic (i.e. it acts as a a melatonin receptor agonist) antidepressant, devoid of the side-effects caused by SSRI, SNRI and tricyclic antidepressants. The drug also has low affinity for 5-HT2C receptors.
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use ![]() |
Used in the treatment of major depressive disorder. |
Mechanism Of Action and Pharmacodynamic Effects ![]() |
Agomelatine is a potent agonist at melatonin receptors and an antagonist at serotonin 5-HT2C receptors. The drug induces noradrenaline and dopamine release in the frontal cortex and the melatonergic effects of agomelatine appear to resynchronise circadian rhythms, thus inducing a phase advance of sleep. It is postulated that the synergy between these two systems is responsible for the drug's psychotropic effects [3]. |
External links ![]() |
For extended ADME data see the following: European Medicines Agency (EMA) |